Study Finds Wegovy Drug Reduces Heart Attack, Stroke Risks by 20%
Written by Susi, Arushi Sharma
In a recent study, the Wegovy drug demonstrated a remarkable reduction of 20% in the risks of heart attacks and strokes.
Novo Nordisk shares surge as Wegovy reduces heart attack and stroke risk by 20%, resulting in a 16.7% increase.
Wegovy's demand surges, affecting manufacturing capacity, driven by celebrity endorsements of Ozempic for diabetes and Wegovy for obesity, both containing semaglutide as an active ingredient.
Novo's drug shows 20% lower cardiovascular risk in overweight patients compared to placebo, according to Bloomberg News.
Pharmaceutical company seeks regulatory approval to expand product use in US and EU due to high cost of medication, over $10,000 annually, affecting many patients.
A 2018 study involving 17,000 patients aged 45+ from 41 countries, focusing on cardiovascular diseases.
Analysts predict Wegovy sales to reach $14 billion due to the boost.